Profile data is unavailable for this security.
About the company
Johnson & Johnson is a holding company that is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates through three segments: Consumer Health, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.
- Revenue in USD (TTM)95.59bn
- Net income in USD18.37bn
- Incorporated1887
- Employees141.70k
- LocationJohnson & JohnsonOne Johnson & Johnson PlazaNEW BRUNSWICK 08933United StatesUSA
- Phone+1 (732) 524-2455
- Fax+1 (732) 214-0332
- Websitehttps://www.jnj.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen, Inc. | 26.38bn | 6.58bn | 132.86bn | 24.20k | 21.36 | 55.74 | 13.56 | 5.11 | 11.80 | 11.80 | 47.50 | 4.52 | 0.4432 | 1.48 | 5.38 | 1,090,248.00 | 11.05 | 11.07 | 14.32 | 13.40 | 75.75 | 79.29 | 24.92 | 30.88 | 1.17 | 7.46 | 0.9379 | 49.28 | 2.18 | 2.47 | -18.87 | -5.26 | 1.01 | 11.97 |
| Bristol-Myers Squibb Co | 47.14bn | 6.62bn | 160.06bn | 32.20k | 24.88 | 4.90 | 9.34 | 3.39 | 3.01 | 3.01 | 21.49 | 15.27 | 0.4465 | 4.58 | 6.00 | 1,464,099.00 | 6.29 | 2.67 | 7.76 | 3.29 | 79.22 | 74.18 | 14.08 | 6.54 | 1.34 | 5.55 | 0.5629 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| Merck & Co., Inc. | 57.17bn | 16.64bn | 226.78bn | 68.00k | 13.60 | 5.22 | 11.13 | 3.95 | 6.56 | 6.53 | 22.53 | 17.07 | 0.5781 | 3.03 | 6.54 | 840,720.60 | 16.84 | 7.61 | 21.83 | 10.14 | 70.77 | 70.92 | 29.13 | 16.06 | 1.15 | 21.89 | 0.4223 | 86.06 | 17.31 | 4.12 | 173.18 | 25.79 | 22.48 | 7.49 |
| AbbVie Inc | 57.35bn | 12.57bn | 247.98bn | 50.00k | 19.93 | 17.01 | 11.92 | 4.35 | 7.07 | 7.07 | 32.27 | 8.29 | 0.3939 | 4.95 | 5.42 | 1,146,980.00 | 8.69 | 7.46 | 11.10 | 9.46 | 70.72 | 72.03 | 22.05 | 18.11 | 0.7456 | 8.27 | 0.8324 | 97.89 | 22.69 | 16.99 | 151.71 | 14.13 | 10.44 | 17.93 |
| Pfizer Inc. | 101.13bn | 29.75bn | 279.31bn | 79.00k | 9.63 | -- | 8.14 | 2.77 | 5.19 | 5.11 | 17.62 | -- | -- | -- | -- | 1,280,152.00 | -- | 6.62 | -- | 8.25 | 62.21 | 74.04 | 29.44 | 21.32 | -- | 22.12 | -- | 75.72 | 95.16 | 9.00 | 238.05 | 25.51 | 6.28 | 5.39 |
| Eli Lilly And Co | 29.07bn | 5.69bn | 287.92bn | 35.00k | 48.61 | 33.87 | 39.63 | 9.96 | 6.27 | 6.27 | 32.02 | 8.99 | 0.6128 | 1.81 | 4.77 | 830,591.40 | 12.00 | 11.08 | 17.83 | 15.80 | 75.98 | 77.16 | 19.58 | 20.77 | 0.846 | 7.33 | 0.6601 | 53.75 | 15.40 | 5.94 | -9.88 | 15.31 | 11.40 | 10.76 |
| Johnson & Johnson | 95.59bn | 18.37bn | 447.43bn | 141.70k | 24.81 | 5.88 | 17.57 | 4.69 | 6.88 | 6.88 | 35.80 | 29.04 | 0.5398 | 2.85 | 6.16 | 674,580.10 | 10.37 | 9.95 | 13.57 | 12.73 | 67.89 | 66.87 | 19.21 | 19.21 | 1.17 | 123.70 | 0.2992 | 62.33 | 13.55 | 5.46 | 44.85 | 4.77 | 2.51 | 5.87 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2022 | 227.92m | 8.66% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 142.23m | 5.41% |
| BlackRock Fund Advisorsas of 31 Mar 2022 | 126.92m | 4.82% |
| Geode Capital Management LLCas of 31 Mar 2022 | 45.02m | 1.71% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2022 | 34.05m | 1.29% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 32.77m | 1.25% |
| State Farm Investment Management Corp.as of 31 Mar 2022 | 31.68m | 1.20% |
| Massachusetts Financial Services Co.as of 31 Mar 2022 | 26.56m | 1.01% |
| BlackRock Investment Management (UK) Ltd.as of 31 Mar 2022 | 25.65m | 0.98% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 24.39m | 0.93% |
